CN106177269A - The pharmaceutical composition of quick curing oral keritonocytes, preparation method and application - Google Patents
The pharmaceutical composition of quick curing oral keritonocytes, preparation method and application Download PDFInfo
- Publication number
- CN106177269A CN106177269A CN201610530228.0A CN201610530228A CN106177269A CN 106177269 A CN106177269 A CN 106177269A CN 201610530228 A CN201610530228 A CN 201610530228A CN 106177269 A CN106177269 A CN 106177269A
- Authority
- CN
- China
- Prior art keywords
- oral
- present
- keritonocytes
- compositions
- component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 239000000203 mixture Substances 0.000 claims abstract description 55
- 208000002399 aphthous stomatitis Diseases 0.000 claims abstract description 18
- 208000007117 Oral Ulcer Diseases 0.000 claims abstract description 17
- 238000002156 mixing Methods 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims abstract description 13
- 208000007287 cheilitis Diseases 0.000 claims abstract description 7
- 210000004195 gingiva Anatomy 0.000 claims abstract description 4
- 208000005232 Glossitis Diseases 0.000 claims abstract description 3
- 201000007100 Pharyngitis Diseases 0.000 claims abstract description 3
- 201000003465 angular cheilitis Diseases 0.000 claims abstract description 3
- 230000008961 swelling Effects 0.000 claims abstract description 3
- 208000016150 acute pharyngitis Diseases 0.000 claims abstract 2
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims description 29
- 239000000284 extract Substances 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 22
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 20
- 239000003795 chemical substances by application Substances 0.000 claims description 19
- 235000019136 lipoic acid Nutrition 0.000 claims description 15
- 229960002663 thioctic acid Drugs 0.000 claims description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 13
- 239000000843 powder Substances 0.000 claims description 12
- 241001116389 Aloe Species 0.000 claims description 10
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 10
- 235000011399 aloe vera Nutrition 0.000 claims description 10
- 229960000304 folic acid Drugs 0.000 claims description 10
- 235000019152 folic acid Nutrition 0.000 claims description 10
- 239000011724 folic acid Substances 0.000 claims description 10
- 239000002674 ointment Substances 0.000 claims description 10
- 239000000243 solution Substances 0.000 claims description 10
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims description 10
- 229960001763 zinc sulfate Drugs 0.000 claims description 10
- 229910000368 zinc sulfate Inorganic materials 0.000 claims description 10
- 239000003921 oil Substances 0.000 claims description 9
- 235000019198 oils Nutrition 0.000 claims description 9
- 239000003826 tablet Substances 0.000 claims description 9
- 240000005481 Salvia hispanica Species 0.000 claims description 8
- 235000001498 Salvia hispanica Nutrition 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 8
- 239000011248 coating agent Substances 0.000 claims description 7
- 238000000576 coating method Methods 0.000 claims description 7
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 235000011187 glycerol Nutrition 0.000 claims description 6
- 235000013599 spices Nutrition 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 239000000945 filler Substances 0.000 claims description 5
- 239000000080 wetting agent Substances 0.000 claims description 5
- 235000004347 Perilla Nutrition 0.000 claims description 4
- 244000124853 Perilla frutescens Species 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 4
- 230000000996 additive effect Effects 0.000 claims description 4
- 235000021388 linseed oil Nutrition 0.000 claims description 4
- 239000000944 linseed oil Substances 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 4
- 239000000758 substrate Substances 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 3
- 238000005469 granulation Methods 0.000 claims description 3
- 230000003179 granulation Effects 0.000 claims description 3
- 239000008298 dragée Substances 0.000 claims description 2
- 239000007941 film coated tablet Substances 0.000 claims description 2
- 235000011837 pasties Nutrition 0.000 claims description 2
- 239000007940 sugar coated tablet Substances 0.000 claims description 2
- 241000196324 Embryophyta Species 0.000 claims 1
- 239000003292 glue Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 27
- 239000002994 raw material Substances 0.000 abstract description 17
- 230000008901 benefit Effects 0.000 abstract description 8
- 201000010099 disease Diseases 0.000 abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 8
- 210000004877 mucosa Anatomy 0.000 abstract description 6
- 206010061218 Inflammation Diseases 0.000 abstract description 5
- 230000036541 health Effects 0.000 abstract description 3
- 230000001954 sterilising effect Effects 0.000 abstract description 3
- 238000004659 sterilization and disinfection Methods 0.000 abstract description 3
- 210000002200 mouth mucosa Anatomy 0.000 abstract description 2
- 238000011084 recovery Methods 0.000 abstract description 2
- 230000007774 longterm Effects 0.000 abstract 1
- 229940046011 buccal tablet Drugs 0.000 description 12
- 239000006189 buccal tablet Substances 0.000 description 12
- 210000000214 mouth Anatomy 0.000 description 10
- 206010011224 Cough Diseases 0.000 description 8
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 206010052428 Wound Diseases 0.000 description 6
- 230000035699 permeability Effects 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000000306 recurrent effect Effects 0.000 description 5
- 244000111489 Gardenia augusta Species 0.000 description 4
- 235000018958 Gardenia augusta Nutrition 0.000 description 4
- 241000241413 Propolis Species 0.000 description 4
- 208000025865 Ulcer Diseases 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 4
- 230000001070 adhesive effect Effects 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000000857 drug effect Effects 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229940069949 propolis Drugs 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 239000004575 stone Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 231100000397 ulcer Toxicity 0.000 description 4
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000034493 Mucous membrane disease Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 230000001741 anti-phlogistic effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 239000000955 prescription drug Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000167880 Hirundinidae Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000005030 aluminium foil Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000002279 cholagogic effect Effects 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000002105 tongue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention provides and a kind of treat the pharmaceutical composition of oral keritonocytes, preparation method and application.In the present composition, by use have can anti-inflammation and sterilization, the innermost layer of mucosa and skin can be penetrated into, the disease sources such as interior free yl can be removed and be of value to the component of oral mucosa growth and recovery as raw material, it is thus possible to the treatment oral keritonocytes such as oral ulcer and glossitis, angular cheilitis, cheilitis, acute pharyngitis or red swelling of gingiva fast and effectively, and then solve in prior art quickly efficient solution to determine the problem of oral keritonocytes.The present composition has component safety and Health, good effect, take effect quick, evident in efficacy and long-term etc. advantage.In the inventive method, by mixing each component in the present invention to prepare pharmaceutical composition of the present invention, there is the advantages such as simple, the simple operation of preparation method.
Description
Technical field
The present invention relates to field of medicinal compositions, concrete, the present invention relates to a kind of quick curing oral keritonocytes
Pharmaceutical composition, preparation method and application.
Background technology
Oral mucosal disease refers to the damage of mucosa in oral cavity, and concrete symptom is: dispute is festered, and tongue body is dry and cracked, then causes mouth
Chamber lichen planus, stomatitis, recurrent aphtha, the oral disease such as cheilitis, cause diet difficulty, oral cavity pain is unbearably.Burst in oral cavity
Infections is noteworthy characterized by recurrent exerbation, and from less to more, position from front to back, is mainly in oral mucosa, gingiva, tongue body to ulcer number
Up and down with side and bottleneck throat, face of festering is greatly such as Semen Glycines, little such as the grain of rice, and surface attachment is festered corruption film.The lighter can occur one the several months
Secondary, the severe one intermission is gradually shortened, and increases the weight of year by year, and even ulcer is risen one after another and reached the several years, many decades is not healed, and may result in internal
Multiple complications, directly affects the healthy of patient and Working Life.At present, numerous to Chinese medicine kind used by this disease clinically
Miscellaneous, but effect is undesirable, and with antibiotic and hormone and biological preparationControlSymptom processed, but be difficult to quickly, and it is susceptible to repeatedly,
So oral mucosal disease is classified as one of oral pathology great difficult problem by medical circles.
Therefore, how rapid, effective treatment oral keritonocytes has just become current problem demanding prompt solution.
In view of this, the special proposition present invention.
Summary of the invention
The first object of the present invention is to provide a kind of active remedy compositions treating oral keritonocytes, of the present invention group
In compound, by use have anti-inflammation and sterilization, good penetrability, can remove the disease sources such as interior free yl and be of value to oral cavity stick
The component of film growth and recovery is as raw material such that it is able to the oral keritonocytes such as rapid, effective treatment oral ulcer, and not
Easily occur repeatedly, and then the problem solving to effect a radical cure oral keritonocytes in prior art.The present composition has component
The advantages such as safety and Health, good effect, instant effect.
The second object of the present invention is to provide the preparation method of a kind of described compositions, in the inventive method, by inciting somebody to action
In the present invention, each component mixes to prepare pharmaceutical composition of the present invention, has the advantages such as simple, the simple operation of preparation method.
Third object of the present invention is to provide the application of the present composition.The present composition is by having safety
The component of effect instant effect is as raw material, thus obtained composition medicine can be effectively used for treating the oral cavities such as oral ulcer
Mucous membrane disease.
In order to realize the above-mentioned purpose of the present invention, spy by the following technical solutions:
A kind of pharmaceutical composition for treating oral keritonocytes, according to percent by weight, described compositions is main
Be made up of following components: Folium Menthae extract 2.0%～3.0%, radix scutellariae extract 3.0%～27%, Aloe powder 1.0%～
3.0%, alpha-lipoic acid 6.0%～47%, Cys 10%～25%, zinc sulfate 1.4%～3.4%, VC 8.0%～
25%, VB2 3.0%～12.0%, VB6 0.50～2.0%, VE 4.0%～16%, folic acid 0.05%～0.4%.
In the present invention, Herba Menthae refreshing and detoxicating, hepatic cholagogic, anti-inflammation, convergence；Radix Scutellariae to multiple gram positive bacteria,
Gram negative bacteria, pathogenic dermatophytes have inhibitory action, antiallergic antioxidation, heat clearing away antiviral, anti-inflammatory analgesic；Aloe has
Have that anticorrosion is moistening, effect of anti-inflammation and sterilization, cell tissue is had protective effect, damaged cell is had the work bringing back to life regeneration simultaneously
With, and wound healing can be promoted；Alpha-lipoic acid has fat-soluble and water solublity, has good percutaneous permeability, can strengthen
Whole free radical resisting material protection net, can increase internal vitamin C and E, glutathion and the concentration of co-ferment Q10, can be effective
Strengthen the vivo immuning system destruction from free radical, it is possible to effectively strengthen vivo immuning system, can also improve relevant simultaneously
The activity of enzyme, also has good protective effect to mucosa；Cysteine is nutritional supplement, antioxidant, has effective solution
Toxic action, and the skin symptom of inflammation and allergy can be improved, maintain the homergy of skin simultaneously；Zinc sulfate can promote wound
Mouth and the healing of wound, enhancing immunity, reduces oral ulcer recurrence；VC is a kind of water miscible strong antioxidant,
The injury that can resist radical pair cell prevents the variation of cell, and can the liver protecting and cell, and play the work of removing toxic substances
By, it is possible to prevention filterable virus and the infection of antibacterial, strengthen function of immune system, increase and tolerate being injured infection pressure power
Power；VB2 is the vitamin of needed by human, to maintaining and to improve the epithelial tissue such as such as alimentary canal mucous membrane tissue significant；
VB6 is to manufacture antibody and erythrocytic necessary material, digestion, absorption protein and fat that can be suitable, helps tryptophan conversion
Become nicotinic acid, prevent the disease of various nerve, skin；Vitamin E can strengthen the antioxidation of cell, maintains various cell membrane
Integrity；Vigor and the receptor etc. that keep membrane bound enzyme act on, effect protected to ulcer；The conjunction of DNA and protein can be promoted
Become；Extend cell survival；Strengthen and exempt from disease activity；Folic acid can play synergism with vitamin C, and protection mucosa is healthy, reduces skin
Infect, improve and safeguard the elasticity of skin.Further, in the present invention, by by above-mentioned have bactericidal antiphlogistic, improve exempt from
Epidemic disease power and promote the component of the effects such as cell migration as raw material and with the use of, and utilize alpha-lipoic acid etc. to have Thief zone
Property raw material with improve the present composition permeability so that the present composition can be quickly concurrent by mucosal absorption
Wave drug action；Meanwhile, in the present invention by by alpha-lipoic acid and the component such as radix scutellariae extract, Vc with the use of, also enter one
Step serves the effect being mutually improved between component, and this also further increases the drug effect of the present composition.Medicine of the present invention
Compositions have component have no side effect safely, instant effect, without repeatedly, it is possible to the effectively advantage such as treatment oral keritonocytes.
In the present invention, it is raw that described VC, VB2, VB6 and VE are respectively vitamin C, vitamin B2, vitamin B6 and dimension
Element E.
Optionally, in the present invention, described Folium Menthae extract is the Folium Menthae extract of 10:1.
Optionally, in the present invention, described radix scutellariae extract is the radix scutellariae extract of 10:1 or 20:1.
Optionally, in the present invention, according to percent by weight, the described pharmaceutical composition for treating oral keritonocytes
Be made up of following components: Folium Menthae extract 2.0%～8.0%, can be such as but be not limited to 3.0%, 4.0%, 5.0%,
6.0%, 7.0%；Radix scutellariae extract 3.0%～27%, can be such as but be not limited to 4.0%, 4.5%, 5.0%, 6.0%,
7.0%, 8.0%, 9.0%, 10%, 11%, 13%, 15%, 17%, 19%, 21%, 23%, 24%, 25%, 26%；Aloe
Powder 1.0%～3.0%, such as, can be but be not limited to 1.2%, 1.5%, 1.6%, 2.0%, 2.4%, 2.6%, 2.8%；α-
Thioctic acid 6.0%～47%, can be such as but be not limited to 6%, 7%, 8%, 9.0%, 10%, 11%, 12%, 15%,
17%, 20%, 25%, 27%, 30%, 33%, 35%, 37%, 40%, 45%；Cys 10%～24%, such as may be used
Think but be not limited to 12%, 15%, 17%, 19%, 20%, 22%；Zinc sulfate 1.4%～3.4%, such as, can be but not limit
In 1.6%, 1.8%, 2.0%, 2.2%, 2.4%, 2.6%, 2.8%, 3.0%, 3.2%；VC 8.0%～20%, such as may be used
Think but be not limited to 9.0%, 10%, 11%, 13%, 15%, 17%, 19%；VB2 3.0%～12%, can be such as but
Be not limited to 4.0%, 5.0%, 5.5%, 6.0%, 6.5%, 7.0%, 7.5%, 8.0%, 8.5%, 9.0%, 9.5%,
10.0%, 10.5%, 11%, 11.5%；VB6 0.50～2.0%, can be such as but be not limited to 0.65%, 0.70%,
0.75%, 0.80%, 0.85%, 1.0%, 1.2%, 1.4%, 1.5%, 1.6%, 1.8%, 1.9%；VE 4.0%～
16%, can be such as but be not limited to 5.0%, 5.5%, 6.0%, 7.0%, 7.5%, 8.0%, 8.5%, 9.0%, 9.5%,
10%, 11%, 12%, 13%, 14%, 15%；Folic acid 0.05%～0.4%, can be such as but be not limited to 0.10%,
0.15%, 0.20%, 0.25%, 0.30%, 0.35%.
Optionally, in the present invention, according to percent by weight, described compositions is mainly made up of following components: Herba Menthae carries
Take thing 2.0%～3.0%, radix scutellariae extract 4.0%～27%, Aloe powder 1.0%～2.4%, alpha-lipoic acid 8.0%～
45%, Cys 10%～24%, zinc sulfate 1.4%～3.4%, VC 8.0%～17%, VB2 3.0%～7%,
VB6 0.55～1.54%, VE 4.0%～14.2%, folic acid 0.05%～0.16%.In the present invention, by former to each component
Adjusting further and optimization of material usage ratio, thus optimize the drug effect of pharmaceutical composition of the present invention further.
Optionally, in the present invention, according to percent by weight, described compositions is made up of following components: Folium Menthae extract
2.0%～3.0%, radix scutellariae extract 3.0%～27%, Aloe powder 1.0%～3.0%, alpha-lipoic acid 6.0%～47%, L-
Cysteine 10%～25%, zinc sulfate 1.4%～3.4%, VC 8.0%～25%, VB2 3.0%～7.0%, VB6
0.55～2.0%, VE 4.0%～16%, folic acid 0.05%～0.4%.
Optionally, in the present invention, the dosage form of described compositions is buccal tablet, film coated tablet, sugar coated tablet, granule
One in agent, powder, capsule, unguentum or solution.
Meanwhile, present invention also offers the preparation method of a kind of pharmaceutical composition for treating oral keritonocytes, institute
After the method for stating comprises the steps: to mix heretofore described component, obtain described for treating the group of oral keritonocytes
Compound.
In the present invention, by present composition mixing is used for, with preparation, the compositions treating oral keritonocytes, tool
There is preparation method simple, the advantage such as prepared drug use convenience, good effect.
Optionally, in the present invention, described method still further comprises after heretofore described component being mixed, and adds auxiliary
Material and/or additive, then prepare the step of composition tablet through granulation, dry, tabletting and coating.
In the present invention, by further present composition preparation being become tablet, thus further facilitate medicine
Containing coughing and buccal.
Optionally, in the present invention, described adjuvant is one or more in filler, lubricant, wetting agent, adhesive
Mixture, described additive is the mixture of one or more in spice or sweeting agent.Optionally, in the present invention, described side
Method still further comprise heretofore described component mixing after, then with glycerine water solution, Salvia Hispanica L. seed oil, perilla oil, Radix Oenotherae erythrosepalae oil
Or after one or more mixing in Linseed oil, furnishing pasty state, to prepare the step of compositions unguentum.
In the present invention, by the present composition is had excellent permeability with glycerine water solution etc., it is possible to strengthen thin
Superoxide dismutase activity suppress the mixing of what anaphylaxis occurred substrate in born of the same parents, thus further increase present invention combination
The permeability of thing and anti-microbial property, and make the present composition take effect faster, sebaceous gland can also be improved further simultaneously
Metabolism, improves endocrine disturbance.
Optionally, in the present invention, the quality of the mixture of described instant component and described glycerine water solution, Salvia Hispanica L.
The quality grams ratio of the substrate of one or more mixing in oil, perilla oil, Radix Oenotherae erythrosepalae oil or Linseed oil is (7-9): (0.5-
3)。
In the present invention, by the adjustment of the matrix ratios such as mixture and glycerol liquor compound and optimization, thus the most excellent
Change the permeability of the present composition, it also avoid the adhesion difference too much caused due to substrate and to drug effect simultaneously
Impact.
Further, present invention also offers the present composition answering in preparation treatment oral keritonocytes medicine
With.
The present invention is by having bactericidal antiphlogistic, improving immunity and promote the component of the effects such as mucosa as raw material also
With the use of, so that pharmaceutical composition of the present invention has good drug effect and permeability, and can effectively treat oral cavity
Mucous membrane disease.
Optionally, in the present invention, described oral keritonocytes is oral ulcer and glossitis, angular cheilitis, cheilitis, acute
The compound oral keritonocytes of one or more in pharyngitis or red swelling of gingiva.
Compared with prior art, the invention have the benefit that
(1) each component safety and Health in the present composition, and synergism between component, can be played, removing certainly simultaneously
Treated by the disease sources such as base, so that the present composition has good curative effect；Meanwhile, had well by interpolation
Infiltrative raw material, also makes the present composition have the innermost layer that can penetrate into mucosa and skin, it is possible to get instant result
Fast onset；
(2) present composition can be prepared as the different dosage form such as tablet or unguentum the most as required, it is possible to is suitable to
Different needs, convenient to use.
(3) present composition can be prepared as tablet or unguentum the most as required for containing coughing, it is also possible to for buccal,
Also can be not only for containing coughing but also for buccal, containing the instant effect coughed, the curative effect of buccal is long.
Detailed description of the invention
Below in conjunction with embodiment, embodiment of the present invention are described in detail, but those skilled in the art will
Understanding, the following example is merely to illustrate the present invention, and is not construed as limiting the scope of the present invention.
In the present invention, Folium Menthae extract (10:1), radix scutellariae extract (20:1) and Aloe powder are by Xi'an Pu Laitesheng
Thing Engineering Co., Ltd provides, and alpha-lipoic acid is provided by Lu An bio tech ltd, Shanghai, and Cys is by Beijing essence
Hua Yaobang Pharmaceutical Technology Co., Ltd provides.Unreceipted actual conditions person in embodiment, advises according to normal condition or manufacturer
Condition carry out.Agents useful for same or instrument unreceipted production firm person, being can be by the commercially available conventional products bought and obtain.
Embodiment 1
According to percetage by weight, weigh appropriate each component raw material respectively.
3.0% Folium Menthae extract (10:1), 3.0% radix scutellariae extract (10:1), 1.0% Aloe powder, 47% alpha-lipoic acid,
10%L-cysteine, 3.4% zinc sulfate, 8.0%VC, 7.0%VB2,1.54%VB6,16%VE and 0.06% folic acid.
Then, after being mixed by raw material, appropriate filler, lubricant, wetting agent, adhesive and spice and sweet taste are added
Agent, then pelletizes, is dried, tabletting and coating processed, obtains the pharmaceutical composition of embodiment 1 containing coughing tablet.Or raw material is mixed
Conjunction obtains raw mixture, then adds Salvia Hispanica L. seed oil in mixture；Wherein, raw mixture quality and Salvia Hispanica L. seed oil quality
Ratio is 7:0.5, continues mixing, obtains the pharmaceutical composition unguentum of embodiment 1.
Comparative example 1: embodiment 1 medicine and Dobell Contrast on effect
Dobell is the key agents of current clinical treatment oral ulcer.
60 volunteers, being selected from through hospital diagnosis is Blood of Patients with Recurrent Oral, is randomly divided into two groups, often organizes 30
People. after 1 group of volunteer of embodiment gargles every day after the meal, coating medicament unguentum at oral ulcer wound surface, every day, coating was real containing 1g
Execute the unguentum 1g of example 1 prescription drug compositions or buccal contain 1g example 1 compound composition medicament containing coughing tablet, points 3～4
Secondary containing coughing, spued after about 20～25 minutes every time；Three times a day, each a piece of Dobell, containing changing in mouth for matched group.So
After, respectively each group of patient being detected every 1 day, and record and statistics oral ulcer situation, experimental result is as follows:
Knowable to above experiment, the embodiment of the present invention 1 is significantly better than current clinic in treatment speed and controls on total effective rate
Treat the key agents Dobell of oral ulcer.
Embodiment 2
According to percetage by weight, 2.0% Folium Menthae extract (10:1), 27% radix scutellariae extract (10:1), 3.0% Aloe powder
(10:1), 8.0% alpha-lipoic acid, 25%L-cysteine, 2.4% zinc sulfate, 25%VC, 3.0%VB2,0.50%VB6,
4.05%VE and 0.05% folic acid.
Weigh appropriate each component raw material respectively, then, after raw material is mixed, add qs Fragrance, sweeting agent and acidity and adjust
Joint agent, makes hard capsule, puts into the self-sealing plastic bag added with deoxidizer bag, additional aluminium foil bag degassing packaging, thus is implemented
The medicament composition capsule agent of example 2.Or by raw material mix after, add appropriate filler, lubricant, wetting agent, adhesive with
And spice and sweeting agent, then pelletize, be dried, tabletting and coating processed, obtain the pharmaceutical composition buccal tablet of embodiment 2.
Comparative example 2: embodiment 2 medicine and stone pungent buccal tablet Contrast on effect
The pungent buccal tablet of stone is the key agents of current clinical treatment oral ulcer.
60 volunteers, being selected from through hospital diagnosis is Blood of Patients with Recurrent Oral, is randomly divided into two groups, often organizes 30
People, after 2 groups of volunteers of embodiment gargle every day after the meal, contains the combination of the present embodiment 2 prescription drug at oral ulcer wound surface buccal
The buccal tablet of thing 1g or capsule, take after 15-20 minute, every natural gift 3～4 buccal；Matched group is three times a day in oral cavity
The pungent buccal tablet of ulcer wound surface buccal stone, the most a piece of, swallow after containing.
Then, point third gear carries out experiments experiment respectively；Wherein, A shelves are continuous use 5 days, and B shelves are continuous use 10 days, C
Shelves are continuous use 15 days, and experimental result is as shown in the table:
Knowable to above experiment, the embodiment of the present invention 2 curative effect of medication phase is significantly better than current clinical treatment oral ulcer
The pungent buccal tablet of key agents stone.
Embodiment 3
According to percetage by weight, weigh appropriate each raw material respectively: 2.0% Folium Menthae extract (10:1), 4.0% Radix Scutellariae extracts
Thing (10:1), 1.0% Aloe powder, 40% alpha-lipoic acid, 10.0%L-cysteine, 1.4% zinc sulfate, 17%VC, 7.0%
VB2,2.0%VB6,15.2%VE and 0.4% folic acid.
Then, each raw material is mixed to get raw mixture, in part material mixture, adds Salvia Hispanica L. seed oil；Wherein,
Raw material mixing quality and Salvia Hispanica L. seed oil mass ratio are 7:0.5, and add spice, sweeting agent and inserts, continue mixing, obtain reality
Execute the pharmaceutical composition unguentum of example 3, for containing coughing；Then, appropriate filler, lubrication are added after being mixed by another part raw material
Agent, wetting agent, adhesive and spice and sweeting agent, then through granulation, dry, tabletting and coating processed, obtain embodiment 3
Pharmaceutical composition buccal tablet.
Comparative example 3 embodiment 3 medicine and Pu Cape jasmine propolis buccal tablet Contrast on effect
Pu Cape jasmine propolis buccal tablet is also the key agents of current clinical treatment oral ulcer.
60 volunteers, being selected from through hospital diagnosis is Blood of Patients with Recurrent Oral, is randomly divided into two groups, often organizes 30
People, after 3 groups of volunteers of embodiment gargle every day after the meal, divides 3～4 times containing coughing at oral ulcer wound surfaceContainThe medicine of the present embodiment 3
The unguentum that compositions 1g is made, told after 15-20 minute, additionally swallowed the pharmaceutical composition containing 0.17g the present embodiment 3 made
Tablet；Matched group takes Pu Cape jasmine propolis buccal tablet three times a day, the most a piece of, swallows after containing.
Divide third gear to test respectively, A shelves for being used in conjunction medicine 5 days, B shelves for being used in conjunction medicine 10 days, C shelves for being used in conjunction medicine 15 days, experiment knot
The most as shown in the table:
Test result indicate that the embodiment of the present invention 3 curative effect phase is significantly better than the key agents of current clinical treatment oral ulcer
Comparative example 3 Pu Cape jasmine propolis buccal tablet.
Effect example 1
In order to be then exhausted from factor with strongest influence power in the 11 kinds of medicaments preferably elected after orthogonal test, carry out
The orthogonal test of 11 factor two levels, has comparative advantage through the power of influence of range analysis result alpha-lipoic acid, is secondly Vc, reed
Luxuriant growth extract, Vb2, cysteine, Radix Scutellariae extract etc..So the maximum feature of the present invention is to apply alpha-lipoic acid.
The oral keritonocytes such as oral ulcer can effectively be treated by present composition medicine, and can fast onset,
And occur period repeatedly longer.It is that one treats the extremely effective medicine of oral keritonocytes.
Although illustrate and describing the present invention with specific embodiment, but it will be appreciated that without departing substantially from the present invention's
May be made that in the case of spirit and scope many other change and amendment.It is, therefore, intended that in the following claims
Including all such changes and modifications belonged in the scope of the invention.
Claims (10)
1. the pharmaceutical composition being used for treating oral keritonocytes, it is characterised in that according to percent by weight, described group
Compound is mainly made up of following components: Folium Menthae extract 2.0%～3.0%, radix scutellariae extract 3.0%～27%, Aloe powder
1.0%～3.0%, alpha-lipoic acid 6.0%～47%, Cys 10%～25%, zinc sulfate 1.4%～3.4%, VC
8.0%～25%, VB2 3.0%～12.0%, VB60.50～2.0%, VE 4.0%～16%, folic acid 0.05%～
0.4%.
Compositions the most according to claim 1, it is characterised in that according to percent by weight, described compositions mainly by
Following components is made: Folium Menthae extract 2.0%～3.0%, radix scutellariae extract 4.0%～27%, Aloe powder 1.0%～2.4%,
Alpha-lipoic acid 8.0%～45%, Cys 10%～24%, zinc sulfate 1.4%～3.4%, VC 8.0%～17%,
VB2 3.0%～7.0%, VB6 0.55～1.54%, VE 4.0%～14.2%, folic acid 0.05%～0.16%.
3. the preparation method being used for treating the pharmaceutical composition of oral keritonocytes, it is characterised in that described method includes
Following steps: after the mixing of component described in any one of claim 1-2, obtain described for treating oral keritonocytes
Compositions.
Method the most according to claim 3, it is characterised in that described method still further comprises enters one by described compositions
Step is processed into the step of tablet, film coated tablet, sugar coated tablet, capsule, powder, powder or solution.
Preparation method the most according to claim 4, it is characterised in that described method still further comprises claim 1-
After component mixing according to any one of 2, add adjuvant and/or additive, then through granulation, dry, tabletting and coating system
Standby composition tablet or the step of glue capsule.
Method the most according to claim 5, it is characterised in that described adjuvant is filler, lubricant, wetting agent or bonding
The mixture of one or more in agent, described additive is the mixture of one or more in spice or sweeting agent.
Method the most according to claim 4, it is characterised in that described method still further comprises in claim 1-2
Described in any one component mixing after, then with in glycerine water solution, Salvia Hispanica L. seed oil, perilla oil, Radix Oenotherae erythrosepalae oil or Linseed oil
Plant or after several mixing, furnishing pasty state, to prepare the step of compositions unguentum.
Method the most according to claim 7, it is characterised in that mixing of component according to any one of described claim 1-2
The quality of compound is mixed with one or more in described glycerine water solution, Salvia Hispanica L. seed oil, perilla oil, Radix Oenotherae erythrosepalae oil or Linseed oil
The quality grams of the substrate closed ratio is (7-9): (0.5-3).
9. the application in preparation treatment oral keritonocytes medicine of the compositions according to any one of claim 1-2.
Application the most according to claim 9, it is characterised in that described oral keritonocytes be oral ulcer and glossitis,
The compound oral keritonocytes of one or more in angular cheilitis, cheilitis, acute pharyngitis or red swelling of gingiva.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610530228.0A CN106177269A (en) | 2016-07-07 | 2016-07-07 | The pharmaceutical composition of quick curing oral keritonocytes, preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610530228.0A CN106177269A (en) | 2016-07-07 | 2016-07-07 | The pharmaceutical composition of quick curing oral keritonocytes, preparation method and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106177269A true CN106177269A (en) | 2016-12-07 |
Family
ID=57472393
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610530228.0A Pending CN106177269A (en) | 2016-07-07 | 2016-07-07 | The pharmaceutical composition of quick curing oral keritonocytes, preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106177269A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106692954A (en) * | 2017-03-27 | 2017-05-24 | 皖南医学院 | Pharmaceutical composition for treating oral ulcer and reagent |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1954844A (en) * | 2005-10-27 | 2007-05-02 | 王加强 | Traditional Chinese medicine for treating macous membrane of mouth disease |
| CN101278994A (en) * | 2007-04-06 | 2008-10-08 | 王洪飞 | Prinsepia utilis Royle oral nursing soft capsules |
| CN104887581A (en) * | 2015-06-11 | 2015-09-09 | 云南天美天康生物科技有限公司 | Oral care composition and preparation method thereof |
| CN105078826A (en) * | 2015-08-26 | 2015-11-25 | 拉芳家化股份有限公司 | Oral care solution |
-
2016
- 2016-07-07 CN CN201610530228.0A patent/CN106177269A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1954844A (en) * | 2005-10-27 | 2007-05-02 | 王加强 | Traditional Chinese medicine for treating macous membrane of mouth disease |
| CN101278994A (en) * | 2007-04-06 | 2008-10-08 | 王洪飞 | Prinsepia utilis Royle oral nursing soft capsules |
| CN104887581A (en) * | 2015-06-11 | 2015-09-09 | 云南天美天康生物科技有限公司 | Oral care composition and preparation method thereof |
| CN105078826A (en) * | 2015-08-26 | 2015-11-25 | 拉芳家化股份有限公司 | Oral care solution |
Non-Patent Citations (2)
| Title |
|---|
| 道良哲: "《延缓老化的整体性途径》", 31 May 2013, 光明日报出版社 * |
| 邹海兰等: "《五官科药物速查手册》", 31 August 2005 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106692954A (en) * | 2017-03-27 | 2017-05-24 | 皖南医学院 | Pharmaceutical composition for treating oral ulcer and reagent |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101780261A (en) | Traditional Chinese medicine composition for treating toothache and preparation method thereof | |
| CN101670051B (en) | Traditional Chinese medicine for treating toothache | |
| CN107951764A (en) | A kind of Chinese medicinal toothpaste for having effects that to prevent canker sore and repair mucous membrane of mouth | |
| CN101396528B (en) | Traditional Chinese medicine composite preparation for treating wind-heat cold | |
| CN106690121A (en) | Trepang, hippophae rhamnoides fruit, cordyceps militaris and selenium preparation and preparation technology thereof | |
| CN106177269A (en) | The pharmaceutical composition of quick curing oral keritonocytes, preparation method and application | |
| CN102872368B (en) | Chinese medicine acupoint application preparation for purging fire for removing toxin | |
| CN109528868A (en) | A kind of Chinese medicine composition treats aphthae in preparation, the application in the drug of carbuncle swells furunculosis | |
| CN103610841A (en) | Method for treating stomatitis of bamboo rats | |
| CN1943635B (en) | Chinese traditional medicinal preparation for treating bone injuries and osteonosus | |
| CN102247444B (en) | Medicine for treating burn and scald and preparation method thereof | |
| CN107496558B (en) | Composition for treating cough and application thereof | |
| CN106511491A (en) | Composition, and preparation method, application and preparation thereof | |
| CN101856476A (en) | Chinese medicament for treating stomachache | |
| CN100431584C (en) | Chinese medicinal formulation for caring and enlarging breast | |
| CN104288379B (en) | Traditional Chinese medicine composition for treating dental ulcer | |
| CN101433576A (en) | Children's antidiarrheal paste | |
| CN105943584A (en) | Medicine for treating dental ulcer | |
| CN105663959A (en) | Traditional Chinese medicine preparation for nursing patient suffering from toothache and preparation method | |
| CN105535658A (en) | Traditional Chinese medicine composition for treating dental ulcer and preparation method thereof | |
| CN105748679A (en) | Traditional Chinese medicine prescription for treating heat toxin and dysentery of pigs | |
| CN104906352A (en) | Traditional Chinese medicine liquid for treating deficiency-fire flaring-up type infantile oral ulcer and preparation method thereof | |
| CN104958653A (en) | Traditional Chinese medicine composition for treating tuberculosis | |
| CN101716275B (en) | Chinese patent medicament for treating osteomyelitis and preparation method | |
| CN112494615A (en) | Traditional Chinese medicine composition, preparation method thereof, oral medicament and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161207 |
|
| RJ01 | Rejection of invention patent application after publication |